Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc.

District Court, W.D. Texas·Decided December 5, 2022·No. 1:20-cv-00783·Unknown

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF TEXAS AUSTIN DIVISION

HOMELAND INSURANCE § COMPANY OF NEW YORK, § Plaintiff § § v. § CIVIL NO. 1-20-CV-783-RP

§ CLINICAL PATHOLOGY § LABORATORIES, INC., § Defendant

ORDER

Now before the Court are Homeland Insurance Company of New York’s Motion for a Protective Order to Quash Certain Categories in Defendants’ Notice of Deposition Pursuant to Rule 30(b)(6), filed October 28, 2022 (Dkt. 164); Homeland Insurance Company of New York’s Motion for Leave to Depose Nancy Stratton After the Discovery Cutoff, filed October 28, 2022 (Dkt. 167); and the associated response and reply briefs. By Text Orders entered November 16, 2022, the District Court referred the motions to the undersigned Magistrate Judge for disposition, pursuant to 28 U.S.C. § 636(b)(1)(A), Federal Rule of Civil Procedure 72, and Rule 1(c) of Appendix C of the Local Rules of the United States District Court for the Western District of Texas (“Local Rules”). I. Background On July 24, 2020, Homeland Insurance Company of New York (“Homeland”) filed this insurance coverage lawsuit against Clinical Pathology Laboratories, Inc. (“CPL”) and CPL’s parent company, Sonic Healthcare USA, Inc. (“Sonic USA”) (collectively, “Defendants”). Dkt. 1. Homeland seeks a declaration that it has no duty to reimburse Defendants for defending medical negligence lawsuits filed against them in Ireland relating to allegedly misread pap smear slides used in cervical cancer screening. Homeland’s Second Amended Complaint, Dkt. 56. Homeland also brings claims for breach of warranty, reformation, and promissory estoppel. Id. Defendants assert several counterclaims against Homeland, including breach of contract, anticipatory breach of contract, violations of the Texas Insurance Code, and a claim for attorneys’ fees. Defendants’ First Amended Counterclaim, Dkt. 46.

Per the Amended Agreed Scheduling Order, the discovery period closed on October 28, 2022, the dispositive motion deadline expired on November 15, 2022, and jury trial is scheduled to commence on February 27, 2023. Dkt. 183. Homeland filed the instant motions on the last day of the discovery period. In its Motion for Leave to Depose Nancy Stratton, Homeland seeks leave under Rule 16(b)(4) to modify the Scheduling Order and depose a former CPL employee after the discovery deadline. In its Motion for a Protective Order under Federal Rule of Civil Procedure 26(c)(1), Homeland seeks to quash certain portions of Defendants’ Rule 30(b)(6) deposition notice. II. Motion for Leave to Depose Nancy Stratton Homeland seeks leave to depose former CPL employee Nancy Stratton, who served as CPL’s

Division Vice President of Quality Improvement and Risk Management and, “during the timeframe relevant to this case,” as CPL’s CEO/President. Dkt. 167 at 3. Homeland contends that Stratton “may have highly relevant and potentially case dispositive information under the prior knowledge exclusion, or because her knowledge can be imputed to CPL.” Id. at 7. A. Local Rule CV-16(e) Local Rule CV-16(e) provides, in relevant part, that: “Notices served before the discovery deadline that purport to schedule depositions after the discovery deadline will not be enforced.” Homeland issued its deposition notice on October 24, 2022, requesting that Stratton appear for a videotaped deposition on November 1, 2022. Dkt. 167-1 at 33 (“Deposition Notice”). Accordingly, the Deposition Notice is untimely and unenforceable under Local Rule 16(e). See Villegas v. M.G. Dyess, Inc., No. 5-19-CV-01057-OLG-RBF, 2021 WL 2593633, at *3 (W.D. Tex. June 23, 2021) (finding that depositions were untimely when requested since “depositions must be completed before the discovery deadline”), R. & R. adopted, 2021 WL 5194901 (W.D. Tex. July 15, 2021). The Court nonetheless may grant Homeland leave to depose Stratton after the discovery deadline

if Homeland shows good cause under Federal Rule of Civil Procedure 16(b)(4). B. Rule 16(b)(4) The Rule 16(b) Scheduling Order in this case required the parties to “complete all discovery on or before October 28, 2022.” Dkt. 183 at 2. Under Rule 16(b)(4), a scheduling order “may be modified only for good cause and with the judge’s consent.” To demonstrate good cause, the party seeking to modify the scheduling order has the burden to show “that the deadlines cannot reasonably be met despite the diligence of the party needing the extension.” Squyres v. Heico Cos., 782 F.3d 224, 237 (5th Cir. 2015). Courts consider the following factors when determining whether the moving party has demonstrated good cause for delay: (1) the explanation for the failure

to timely comply with the scheduling order; (2) the importance of the modification of the scheduling order; (3) potential prejudice in allowing the modification; and (4) the availability of a continuance to cure such prejudice. Id. The Court considers the four good cause factors in turn. 1. Homeland’s Explanation Homeland asserts that it “diligently pursued Ms. Stratton’s deposition,” but the record does not support this argument. Dkt. 167 at 5. Homeland first sought Stratton’s deposition on January 18, 2022, when it served on CPL a Notice of Deposition for Stratton’s videotaped deposition on February 22, 2022. Dkt. 167-1 at 73. Homeland contends that the deposition did not take place because CPL’s counsel told Homeland’s counsel that he had “scheduling conflicts.” Brooks Decl., Dkt. 167-2 ¶ 2. Homeland did not contact CPL about rescheduling Stratton’s deposition until September 23, 2022, when Homeland’s counsel emailed CPL’s counsel to inquire about dates for several depositions, including Stratton’s. Dkt. 167-1 at 16. Homeland appears to suggest that it did not

pursue rescheduling Stratton’s deposition sooner because it was busy with “significant written discovery,” resulting in “submission of significant motions to compel the production of thousands of pages of documents, two of which are still pending before the Court.” Dkt. 167 at 3.1 CPL responded to Homeland’s email on September 28, 2022, stating: “We do not represent Ms. Stratton at this time, and so cannot accept service of a subpoena for her deposition.” Dkt. 167-1 at 20. Homeland contends that it then sought Stratton’s contact information and reached out to her directly on October 3, 2022. Dkt. 167 at 3. However, “soon thereafter, CPL’s counsel informed Homeland that Ms. Stratton had reached out to CPL through counsel and that CPL was now in contact with her.” Id. at 3-4. On October 11 and October 19, 2022, Homeland’s counsel emailed

CPL’s counsel asking if he had any update on Stratton and whether Homeland should reach out to Stratton’s new counsel. Dkt. 167-1 at 26. Homeland alleges that on October 21, 2022, CPL’s counsel informed Homeland’s counsel that “it could not accept service or coordinate Ms. Stratton’s deposition, and that Ms. Stratton may or may not still be represented.” Brooks Decl., Dkt. 167-1 ¶ 8. On October 24, 2022, Homeland served on Stratton a testimony subpoena directing her to appear for a deposition by videoconference on November 1, 2022. Dkt. 167-1 at 33.

Free access — add to your briefcase to read the full text and ask questions with AI

Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc., (W.D. Tex. 2022).

Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc. (Homeland Insurance Company of New York v. Clinical Pathology Laboratories, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related